Earlier this month, the Centers for Medicare and Medicaid Services announced that Medicare would cover Aduhelm, the first Alzheimer’s medication approved by the Food and Drug Administration in nearly two decades. But just a tiny subset of beneficiaries with the neurodegenerative disease will be covered.

The agency’s decision to more or less ration access to Aduhelm could gut research efforts into drugs for other diseases without effective treatments.